Cancer Vaccine Trial Offers New Hope for Patients

By Effie Kagbala

A personalised cancer vaccine developed by pharmaceutical giants Moderna and Merck has shown promising results in preventing the return and spread of melanoma, an aggressive form of skin cancer.

Early findings from a major Phase 3 clinical trial involving more than 1,000 patients indicate that combining the vaccine with Keytruda, an established immunotherapy drug, kept patients cancer-free for longer than treatment with Keytruda alone.

The trial involved patients diagnosed with high-risk stage two, three and four melanoma following surgery to remove their tumours. The participants ranged from those with large, localised tumours to patients whose cancer had already spread.

The companies said the combination treatment also reduced the risk of melanoma spreading to other parts of the body.

How the personalised vaccine works

Unlike conventional vaccines designed to prevent infectious diseases, the treatment is tailored to each patient's tumour.

Using mRNA technology, the same technology used in some COVID-19 vaccines, scientists analyse the genetic makeup of a patient's tumour after surgery and identify mutations unique to the cancer.

The resulting personalised vaccine is designed to train the patient's immune system to recognise and attack cancer cells that may remain in the body and potentially cause the disease to return.

Moderna Chief Executive, Stephane Bancel, described the findings as a "pivotal moment" in cancer research, saying they could help shape the future of personalised cancer treatment.

However, medical experts have urged caution, stressing that the full results of the trial have not yet been published or independently reviewed.

Dr Talisia Quallo, Head of Prevention and Early Detection at Cancer Research UK, said the findings showed promise but required further assessment.

She stressed the importance of continued investment in cancer research to expand access to personalised treatments capable of helping patients live longer and healthier lives.

Dr Lennard Lee, a consultant medical oncologist and associate professor at the University of Oxford, also described the findings as encouraging for melanoma patients.

He said the study provided "proof of principle" that personalised cancer vaccines could work and potentially have broader applications in cancer treatment.

Wider cancer applications

The treatment is not yet available for routine use. It must undergo regulatory approval before it can be introduced widely, including through healthcare systems such as the UK's National Health Service.

Merck and Moderna are also investigating similar personalised mRNA vaccines for other forms of cancer, including lung, bladder and kidney cancers.

If subsequent analysis confirms the initial findings, the breakthrough could mark an important step towards cancer treatment tailored to the genetic characteristics of individual patients.